Clinical trials
Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 225 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT05254171RecruitingPhase 2/Phase 3
Trial adds SBP-101 to standard chemo for pancreatic cancer
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
Hot Springs, ArkansasAges 18 years+ - NCT05346536Recruiting
Test blood test for a specific type of pancreatic cancer cell
This trial looks for pancreatic cancer markers in a blood sample (“liquid biopsy”), focusing on cells that show a certain protein (AXL). It may help doctors detect and better track advanced pancreatic cancer before or during first-line treatment.
MontpellierAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05518903RecruitingPhase 2
Scan test to see tumor-support cells in pancreatic cancer
This trial tests a special imaging scan (a PET/CT with a tracer called 68Ga-FAPI-46) to look at “cancer-support” cells in people with localized pancreatic ductal adenocarcinoma. It may help doctors better understand the tumor and how it responds before surgery after initial treatment.
Rochester, MinnesotaAges 18 years+ - NCT05526443Recruiting
Registry study for advanced pancreatic cancer treatment patterns
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Graz, StyriaAges 18 years+ - NCT05723107RecruitingPhase 1
Testing an endoscopic treatment for pancreatic cancer that can't be removed
This early-phase trial is testing a new endoscopic (from inside the stomach) approach for pancreatic ductal adenocarcinoma that is locally advanced and cannot be removed with surgery. It may help some people who have already tried first chemotherapy and still have a tumor confined to the pancreas area (no spread).
New York, New YorkAges 18 years+ - NCT05727020Recruiting
Breath test study for pancreatic cancer and related conditions
This study checks whether breathing out certain chemicals (volatile organic compounds) can help identify pancreatic ductal adenocarcinoma (pancreatic cancer) or related pancreas problems. You may qualify if you’re an adult with suspected/confirmed pancreatic conditions and can safely take part in breath testing or surgery-related tissue collection.
LondonAges 18 years+ - NCT05927142RecruitingPhase 1/Phase 2
Durvalumab plus rintatolimod for metastatic pancreatic cancer
This early-phase study tests whether adding rintatolimod to durvalumab can improve outcomes for people with metastatic pancreatic cancer. It aims to see if this combination can better activate the immune system against the cancer after initial chemotherapy.
Rotterdam, South HollandAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Jacksonville, FloridaAges 18 years+ - NCT06041009Recruiting
Pancreatic cancer screening with a new enzyme test
This study is testing if measuring a substance called elastase-1, along with standard tests, can help find pancreatic cancer earlier. It may benefit people who already have signs of pancreatic disease or are at high risk.
Jinan, ShandongAges 18 years+ - NCT06122896RecruitingEarly Phase 1
Screening for pancreatic cancer in high-risk people
This trial uses MRI and endoscopic ultrasound to look for early signs of pancreatic cancer in people who have a high risk due to their genes or family history. Finding it early may lead to better treatment options.
Boston, MassachusettsAges 18 years+ - NCT06141031RecruitingPhase 1
TTI-101 plus radiation for borderline or locally advanced pancreatic cancer
This trial tests a new oral drug (TTI-101) combined with targeted radiation (SBRT) for people with pancreatic cancer that is not removable by surgery. It aims to see if this combination helps shrink tumors that are borderline resectable or locally advanced.
Aurora, ColoradoAges 18 years+ - NCT06151223Recruiting
Pancreatic cancer risk registry for high-risk individuals
This study is a registry for people at high risk for pancreatic cancer. Researchers will collect information over time to learn more about how to detect and prevent the disease.
Rochester, MinnesotaAges 18 years+ - NCT06287749Recruiting
Liquid biopsy for monitoring pancreatic cancer after surgery
This trial is testing a blood test (liquid biopsy) to look for tiny traces of cancer DNA after surgery for pancreatic cancer. It may help doctors understand if the cancer is likely to come back.
Montpellier, HéraultAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New Haven, ConnecticutAges 18 years+ - NCT06330441Recruiting
Pancreatic cancer screening for high-risk groups
This study screens people at high risk for pancreatic cancer using imaging tests. It aims to catch cancer early in those with certain genetic conditions or strong family history.
BrnoAges 18 years+ - NCT06423326RecruitingPhase 2
Chemotherapy before surgery for pancreatic cancer
This trial tests a three-drug chemotherapy combination (gemcitabine, cisplatin, and nab-paclitaxel) given before surgery for people with pancreatic cancer that can be removed or is on the edge of being removable. The goal is to shrink the tumor and improve surgery outcomes.
Atlanta, GeorgiaAges 18 years+ - NCT06427239RecruitingPhase 1/Phase 2
HRS-4642 and adebrelimab for advanced pancreatic cancer
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Chandler, ArizonaAges 18 years+ - NCT06454383RecruitingPhase 1
Gemcitabine and leflunomide for advanced pancreatic cancer
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Duarte, CaliforniaAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Duarte, CaliforniaAges 18 years+ - NCT06549725Recruiting
Lipidica software for pancreatic cancer screening
This trial tests a software that analyzes fats (lipids) in your blood to find pancreatic cancer early. You may join if you have pancreatic cancer that can be removed with surgery, or if you are at very high risk due to family history or certain gene mutations.
Prague, CzechiaAges 18 years+ - NCT06595160Recruiting
Diet and gut bacteria in pancreatic cancer treatment
This study looks at how diet and the bacteria in your gut might affect how well chemotherapy works for pancreatic cancer that can be surgically removed. If you have been newly diagnosed with this type of pancreatic cancer, you may be able to join.
Atlanta, GeorgiaAges 18 years+
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 225 recruiting pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Unresectable Pancreatic Ductal Adenocarcinoma
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.